Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 629 entries
Sorted by: Best Match Show Resources per page
Correction to: Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance.

Reviews of physiology, biochemistry and pharmacology

Momtazi-Borojeni AA, Mosafer J, Nikfar B, Ekhlasi-Hundrieser M, Chaichian S, Mehdizadehkashi A, Vaezi A.
PMID: 30610398
Rev Physiol Biochem Pharmacol. 2019;176:131. doi: 10.1007/112_2018_14.

The affiliation of the 6th author Dr. Abolfazl Mehdizadehkashi was incorrect. It has been corrected to Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.

Cite
Momtazi-Borojeni AA, Mosafer J, Nikfar B, et al. Correction to: Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance. Rev Physiol Biochem Pharmacol. 2019;176:131doi: 10.1007/112_2018_14.
Momtazi-Borojeni, A. A., Mosafer, J., Nikfar, B., Ekhlasi-Hundrieser, M., Chaichian, S., Mehdizadehkashi, A., & Vaezi, A. (2019). Correction to: Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance. Reviews of physiology, biochemistry and pharmacology, 176131. https://doi.org/10.1007/112_2018_14
Momtazi-Borojeni, Amir Abbas, et al. "Correction to: Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance." Reviews of physiology, biochemistry and pharmacology vol. 176 (2019): 131. doi: https://doi.org/10.1007/112_2018_14
Momtazi-Borojeni AA, Mosafer J, Nikfar B, Ekhlasi-Hundrieser M, Chaichian S, Mehdizadehkashi A, Vaezi A. Correction to: Curcumin in Advancing Treatment for Gynecological Cancers with Developed Drug- and Radiotherapy-Associated Resistance. Rev Physiol Biochem Pharmacol. 2019;176:131. doi: 10.1007/112_2018_14. PMID: 30610398.
Copy Download .nbib Format: NLM
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways.

Biochemical pharmacology

Yu J, Zhang L, Peng J, Ward R, Hao P, Wang J, Zhang N, Yang Y, Guo X, Xiang C, An S, Xu TR.
PMID: 34861243
Biochem Pharmacol. 2021 Nov 30;195:114864. doi: 10.1016/j.bcp.2021.114864. Epub 2021 Nov 30.

Dictamnine (Dic), a naturally occurring small-molecule furoquinoline alkaloid isolated from the root bark of Dictamnus dasycarpus Turcz., is reported to display anticancer properties. However, little is known about the direct target proteins and anticancer mechanisms of Dic. In the...

Cite
Yu J, Zhang L, Peng J, et al. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2021;195:114864doi: 10.1016/j.bcp.2021.114864.
Yu, J., Zhang, L., Peng, J., Ward, R., Hao, P., Wang, J., Zhang, N., Yang, Y., Guo, X., Xiang, C., An, S., & Xu, T. R. (2021). Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochemical pharmacology, 195114864. https://doi.org/10.1016/j.bcp.2021.114864
Yu, Jiaojiao, et al. "Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways." Biochemical pharmacology vol. 195 (2021): 114864. doi: https://doi.org/10.1016/j.bcp.2021.114864
Yu J, Zhang L, Peng J, Ward R, Hao P, Wang J, Zhang N, Yang Y, Guo X, Xiang C, An S, Xu TR. Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochem Pharmacol. 2021 Nov 30;195:114864. doi: 10.1016/j.bcp.2021.114864. Epub 2021 Nov 30. PMID: 34861243.
Copy Download .nbib Format: NLM
The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives.

Biochemical pharmacology

Bailly C.
PMID: 34968491
Biochem Pharmacol. 2021 Dec 28;197:114895. doi: 10.1016/j.bcp.2021.114895. Epub 2021 Dec 28.

Amlexanox (AMX) is an azoxanthone drug used for decades for the treatment of mouth aphthous ulcers and now considered for the treatment of diabetes and obesity. The drug is usually viewed as a dual inhibitor of the non-canonical IκB...

Cite
Bailly C. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochem Pharmacol. 2021;197:114895doi: 10.1016/j.bcp.2021.114895.
Bailly, C. (2021). The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochemical pharmacology, 197114895. https://doi.org/10.1016/j.bcp.2021.114895
Bailly, Christian. "The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives." Biochemical pharmacology vol. 197 (2021): 114895. doi: https://doi.org/10.1016/j.bcp.2021.114895
Bailly C. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives. Biochem Pharmacol. 2021 Dec 28;197:114895. doi: 10.1016/j.bcp.2021.114895. Epub 2021 Dec 28. PMID: 34968491.
Copy Download .nbib Format: NLM
Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells.

Biochemical pharmacology

Hu WY, Lu R, Hu DP, Imir OB, Zuo Q, Moline D, Afradiasbagharani P, Liu L, Lowe S, Birch L, Griend DJV, Madak-Erdogan Z, Prins GS.
PMID: 34968493
Biochem Pharmacol. 2021 Dec 27;197:114902. doi: 10.1016/j.bcp.2021.114902. Epub 2021 Dec 27.

Per- and polyfluorinated alkyl substances (PFAS) are a large family of widely used synthetic chemicals that are environmentally and biologically persistent and present in most individuals. Chronic PFAS exposure have been linked to increased prostate cancer risk in occupational...

Cite
Hu WY, Lu R, Hu DP, et al. Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochem Pharmacol. 2021;197:114902doi: 10.1016/j.bcp.2021.114902.
Hu, W. Y., Lu, R., Hu, D. P., Imir, O. B., Zuo, Q., Moline, D., Afradiasbagharani, P., Liu, L., Lowe, S., Birch, L., Griend, D. J. V., Madak-Erdogan, Z., & Prins, G. S. (2021). Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochemical pharmacology, 197114902. https://doi.org/10.1016/j.bcp.2021.114902
Hu, Wen-Yang, et al. "Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells." Biochemical pharmacology vol. 197 (2021): 114902. doi: https://doi.org/10.1016/j.bcp.2021.114902
Hu WY, Lu R, Hu DP, Imir OB, Zuo Q, Moline D, Afradiasbagharani P, Liu L, Lowe S, Birch L, Griend DJV, Madak-Erdogan Z, Prins GS. Per- and polyfluoroalkyl substances target and alter human prostate stem-progenitor cells. Biochem Pharmacol. 2021 Dec 27;197:114902. doi: 10.1016/j.bcp.2021.114902. Epub 2021 Dec 27. PMID: 34968493.
Copy Download .nbib Format: NLM
Patterns of Ciliation and Ciliary Signaling in Cancer.

Reviews of physiology, biochemistry and pharmacology

Kiseleva AA, Nikonova AS, Golemis EA.
PMID: 32761455
Rev Physiol Biochem Pharmacol. 2020 Aug 07; doi: 10.1007/112_2020_36. Epub 2020 Aug 07.

Among the factors that have been strongly implicated in regulating cancerous transformation, the primary monocilium (cilium) has gained increasing attention. The cilium is a small organelle extending from the plasma membrane, which provides a localized hub for concentration of...

Cite
Kiseleva AA, Nikonova AS, Golemis EA. Patterns of Ciliation and Ciliary Signaling in Cancer. Rev Physiol Biochem Pharmacol. 2020;doi: 10.1007/112_2020_36.
Kiseleva, A. A., Nikonova, A. S., & Golemis, E. A. (2020). Patterns of Ciliation and Ciliary Signaling in Cancer. Reviews of physiology, biochemistry and pharmacology, . https://doi.org/10.1007/112_2020_36
Kiseleva, Anna A, et al. "Patterns of Ciliation and Ciliary Signaling in Cancer." Reviews of physiology, biochemistry and pharmacology vol. (2020). doi: https://doi.org/10.1007/112_2020_36
Kiseleva AA, Nikonova AS, Golemis EA. Patterns of Ciliation and Ciliary Signaling in Cancer. Rev Physiol Biochem Pharmacol. 2020 Aug 07; doi: 10.1007/112_2020_36. Epub 2020 Aug 07. PMID: 32761455.
Copy Download .nbib Format: NLM
CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs.

Biochemical pharmacology

Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP.
PMID: 34748821
Biochem Pharmacol. 2021 Dec;194:114824. doi: 10.1016/j.bcp.2021.114824. Epub 2021 Nov 05.

Diphenylamine NSAIDs are taken frequently for chronic pain conditions, yet their use may potentiate hepatotoxicity risks through poorly characterized metabolic mechanisms. Our previous work revealed that seven marketed or withdrawn diphenylamine NSAIDs undergo bioactivation into quinone-species metabolites, whose reaction...

Cite
Schleiff MA, Crosby S, Blue M, et al. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021;194:114824doi: 10.1016/j.bcp.2021.114824.
Schleiff, M. A., Crosby, S., Blue, M., Schleiff, B. M., Boysen, G., & Miller, G. P. (2021). CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochemical pharmacology, 194114824. https://doi.org/10.1016/j.bcp.2021.114824
Schleiff, Mary Alexandra, et al. "CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs." Biochemical pharmacology vol. 194 (2021): 114824. doi: https://doi.org/10.1016/j.bcp.2021.114824
Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 Dec;194:114824. doi: 10.1016/j.bcp.2021.114824. Epub 2021 Nov 05. PMID: 34748821.
Copy Download .nbib Format: NLM
Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688].

Biochemical pharmacology

Kasembeli MM, Singhmar P, Ma J, Edralin J, Tang Y, Adams C, Heijnen CJ, Kavelaars A, Tweardy DJ.
PMID: 34864607
Biochem Pharmacol. 2022 Jan;195:114860. doi: 10.1016/j.bcp.2021.114860. Epub 2021 Dec 02.

No abstract available.

Cite
Kasembeli MM, Singhmar P, Ma J, et al. Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688]. Biochem Pharmacol. 2021;195:114860doi: 10.1016/j.bcp.2021.114860.
Kasembeli, M. M., Singhmar, P., Ma, J., Edralin, J., Tang, Y., Adams, C., Heijnen, C. J., Kavelaars, A., & Tweardy, D. J. (2022). Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688]. Biochemical pharmacology, 195114860. https://doi.org/10.1016/j.bcp.2021.114860
Kasembeli, Moses M, et al. "Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688]." Biochemical pharmacology vol. 195 (2022): 114860. doi: https://doi.org/10.1016/j.bcp.2021.114860
Kasembeli MM, Singhmar P, Ma J, Edralin J, Tang Y, Adams C, Heijnen CJ, Kavelaars A, Tweardy DJ. Corrigendum to "TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain" [Biochem. Pharmacol. 192 (2021) 114688]. Biochem Pharmacol. 2022 Jan;195:114860. doi: 10.1016/j.bcp.2021.114860. Epub 2021 Dec 02. PMID: 34864607; PMCID: PMC8718107.
Copy Download .nbib Format: NLM
Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell.

Biochemical pharmacology

Kowluru A, Gleason NF.
PMID: 34968495
Biochem Pharmacol. 2021 Dec 28;197:114886. doi: 10.1016/j.bcp.2021.114886. Epub 2021 Dec 28.

Rho subfamily of G proteins (e.g., Rac1) have been implicated in glucose-stimulated insulin secretion from the pancreatic β-cell. Interestingly, metabolic stress (e.g., chronic exposure to high glucose) results in sustained activation of Rac1 leading to increased oxidative stress, impaired...

Cite
Kowluru A, Gleason NF. Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell. Biochem Pharmacol. 2021;197:114886doi: 10.1016/j.bcp.2021.114886.
Kowluru, A., & Gleason, N. F. (2021). Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell. Biochemical pharmacology, 197114886. https://doi.org/10.1016/j.bcp.2021.114886
Kowluru, Anjaneyulu, and Gleason, Noah F. "Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell." Biochemical pharmacology vol. 197 (2021): 114886. doi: https://doi.org/10.1016/j.bcp.2021.114886
Kowluru A, Gleason NF. Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell. Biochem Pharmacol. 2021 Dec 28;197:114886. doi: 10.1016/j.bcp.2021.114886. Epub 2021 Dec 28. PMID: 34968495.
Copy Download .nbib Format: NLM
Identification of ritanserin analogs that display DGK isoform specificity.

Biochemical pharmacology

Granade ME, Manigat LC, Lemke MC, Purow BW, Harris TE.
PMID: 34999054
Biochem Pharmacol. 2022 Jan 06;197:114908. doi: 10.1016/j.bcp.2022.114908. Epub 2022 Jan 06.

The diacylglycerol kinase (DGK) family of lipid enzymes catalyzes the conversion of diacylglycerol (DAG) to phosphatidic acid (PA). Both DAG and PA are lipid signaling molecules that are of notable importance in regulating cell processes such as proliferation, apoptosis,...

Cite
Granade ME, Manigat LC, Lemke MC, et al. Identification of ritanserin analogs that display DGK isoform specificity. Biochem Pharmacol. 2022;197:114908doi: 10.1016/j.bcp.2022.114908.
Granade, M. E., Manigat, L. C., Lemke, M. C., Purow, B. W., & Harris, T. E. (2022). Identification of ritanserin analogs that display DGK isoform specificity. Biochemical pharmacology, 197114908. https://doi.org/10.1016/j.bcp.2022.114908
Granade, Mitchell E, et al. "Identification of ritanserin analogs that display DGK isoform specificity." Biochemical pharmacology vol. 197 (2022): 114908. doi: https://doi.org/10.1016/j.bcp.2022.114908
Granade ME, Manigat LC, Lemke MC, Purow BW, Harris TE. Identification of ritanserin analogs that display DGK isoform specificity. Biochem Pharmacol. 2022 Jan 06;197:114908. doi: 10.1016/j.bcp.2022.114908. Epub 2022 Jan 06. PMID: 34999054.
Copy Download .nbib Format: NLM
Pyrroloquinoline quinone attenuated benzyl butyl phthalate induced metabolic aberration and a hepatic metabolomic analysis.

Biochemical pharmacology

Zhang J, Powell C, Meruvu S, Sonkar R, Choudhury M.
PMID: 34971587
Biochem Pharmacol. 2021 Dec 29;197:114883. doi: 10.1016/j.bcp.2021.114883. Epub 2021 Dec 29.

Benzyl butyl phthalate (BBP) has recently been implicated as an obesogen. Our recent study demonstrated that BBP can exacerbate high fat diet (HFD) induced diabesity in male mice. Here, we explored if pyrroloquinoline quinone (PQQ), a natural antioxidant andphytochemical,...

Cite
Zhang J, Powell C, Meruvu S, et al. Pyrroloquinoline quinone attenuated benzyl butyl phthalate induced metabolic aberration and a hepatic metabolomic analysis. Biochem Pharmacol. 2021;197:114883doi: 10.1016/j.bcp.2021.114883.
Zhang, J., Powell, C., Meruvu, S., Sonkar, R., & Choudhury, M. (2021). Pyrroloquinoline quinone attenuated benzyl butyl phthalate induced metabolic aberration and a hepatic metabolomic analysis. Biochemical pharmacology, 197114883. https://doi.org/10.1016/j.bcp.2021.114883
Zhang, Jian, et al. "Pyrroloquinoline quinone attenuated benzyl butyl phthalate induced metabolic aberration and a hepatic metabolomic analysis." Biochemical pharmacology vol. 197 (2021): 114883. doi: https://doi.org/10.1016/j.bcp.2021.114883
Zhang J, Powell C, Meruvu S, Sonkar R, Choudhury M. Pyrroloquinoline quinone attenuated benzyl butyl phthalate induced metabolic aberration and a hepatic metabolomic analysis. Biochem Pharmacol. 2021 Dec 29;197:114883. doi: 10.1016/j.bcp.2021.114883. Epub 2021 Dec 29. PMID: 34971587.
Copy Download .nbib Format: NLM
Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy.

Biochemical pharmacology

Li Z, Yao Q, Tian Y, Jiang Y, Xu M, Wang H, Xiong Y, Fang J, Lu W, Yu D, Shi H.
PMID: 34971589
Biochem Pharmacol. 2021 Dec 28;197:114904. doi: 10.1016/j.bcp.2021.114904. Epub 2021 Dec 28.

Cisplatin is a widely used chemotherapeutic agent for the treatment of various tumors, but its side effects limit its application. Ototoxicity, a major adverse effect of cisplatin, causes irreversible sensorineural hearing loss. Unfortunately, there are no effective approaches to...

Cite
Li Z, Yao Q, Tian Y, et al. Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy. Biochem Pharmacol. 2021;197:114904doi: 10.1016/j.bcp.2021.114904.
Li, Z., Yao, Q., Tian, Y., Jiang, Y., Xu, M., Wang, H., Xiong, Y., Fang, J., Lu, W., Yu, D., & Shi, H. (2021). Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy. Biochemical pharmacology, 197114904. https://doi.org/10.1016/j.bcp.2021.114904
Li, Zhuangzhuang, et al. "Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy." Biochemical pharmacology vol. 197 (2021): 114904. doi: https://doi.org/10.1016/j.bcp.2021.114904
Li Z, Yao Q, Tian Y, Jiang Y, Xu M, Wang H, Xiong Y, Fang J, Lu W, Yu D, Shi H. Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy. Biochem Pharmacol. 2021 Dec 28;197:114904. doi: 10.1016/j.bcp.2021.114904. Epub 2021 Dec 28. PMID: 34971589.
Copy Download .nbib Format: NLM
Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery.

Biochemical pharmacology

Perveen S, Sharma R.
PMID: 34990594
Biochem Pharmacol. 2022 Jan 04;197:114906. doi: 10.1016/j.bcp.2021.114906. Epub 2022 Jan 04.

Tuberculosis (TB) is an infectious disease, infecting a quarter of world's population. Drug resistant TB further exacerbates the grim scenario of the drying TB drug discovery pipeline. The limited arsenal to fight TB presses the need for thorough efforts...

Cite
Perveen S, Sharma R. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery. Biochem Pharmacol. 2022;197:114906doi: 10.1016/j.bcp.2021.114906.
Perveen, S., & Sharma, R. (2022). Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery. Biochemical pharmacology, 197114906. https://doi.org/10.1016/j.bcp.2021.114906
Perveen, Summaya, and Sharma, Rashmi. "Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery." Biochemical pharmacology vol. 197 (2022): 114906. doi: https://doi.org/10.1016/j.bcp.2021.114906
Perveen S, Sharma R. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery. Biochem Pharmacol. 2022 Jan 04;197:114906. doi: 10.1016/j.bcp.2021.114906. Epub 2022 Jan 04. PMID: 34990594.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 629 entries